REFERENCES
- Park Y, Kim JW, Kim DS, . The bone morphogenesis protein-2 (BMP-2) is associated with progression to metastatic disease in gastric cancer. Cancer Res Treat. 2008;40:127–132.
- Yang YL, Liu YS, Chuang LY, . Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-β receptors. Endocrinology. 2009;150:727–740.
- Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is type II acute-phase protein. Blood. 2003;101:2461–2463.
- Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenic proteins 4 and 9. Br J Hematol. 2007;139:138–147.
- Costa E, Pereira BJG, Rocha-Pereira P, . Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol. 2008;28:677–683.
- Locatelli F, Aljama P, Barany P, . European best practice guidelines working group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl. 2):ii1–ii47.
- Deicher R, Horl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest. 2006;36:301–309.
- Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol Mech Dis. 2009;4:489–515.
- Kattamis A, Papassotiriou I, Palaiologou D, . The effects of erythropoietic activity and iron burdenon hepcidin expression in patients with thalassemia major. Hematologica. 2006;91:809–812.
- Babitt JL, Huang FW, Wrighting DM, . Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genetic. 2006;38:531–539.
- Costa E, Rocha S, Rocha-Pereira P, . Crosstalk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis in hemodialysis patients. J Vasc Access. 2008;9(4):248–253.